Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KPE02004001
- Development stage
- Unknown
- Lead developer
- Kissei Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KPE02004001 is an investigational small molecule being developed by Kissei Pharmaceutical for the treatment of primary biliary cholangitis (PBC). It functions as a selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). By activating PPARδ, the drug aims to regulate bile acid synthesis, transport, and inflammation within the liver, potentially reducing the cholestatic injury and fibrosis associated with PBC. It is currently being evaluated in clinical trials to assess its safety, tolerability, and efficacy in patients who have an inadequate response to or are intolerant of ursodeoxycholic acid (UDCA).
02
Targets
PPARD (Peroxisome proliferator–activated receptor delta)
Beyond the preview
Go deeper on KPE02004001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KPE02004001.